| (Astellas) 2215-CL-0304 / BMT CTN 1506 | A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML | Leber, Dr Brian | Open to recruitment | NCT02997202 |
| (Celgene) ACE-536-MDS-002 / COMMANDS | A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions | Leber, Dr Brian | Open to recruitment | NCT03682536 |
| (Constellation) CPI-0610-02 / MANIFEST study | A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis) | Leber, Dr Brian | Open to recruitment | NCT02158858 |
| (Pfizer) B1761031 | A Single Arm, Open-label, Phase 4 Study Evaluating Qt Interval, Pharmacokinetics, And Safety Of Gemtuzumab Ozogamicin (Mylotarg (Trademarker)) As A Single-agent Regimen In Patients With Relapsed Or Refractory Cd33-positive Acute Myeloid Leukemia | Leber, Dr Brian | Open to recruitment | NCT03727750 |
| (UHN) CFI-400945-CL-002 | An Open-Label, Dose Escalation, Safety and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Leber, Dr Brian | Open to recruitment | NCT03187288 |
| (UHN) SMART-AML-001 | Feasibility and validation study of the LSC17 score in acute myeloid leukemia (AML) patients | Leber, Dr Brian | Open to recruitment | |
| (CCTG) LY.17 | A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Fraser, Dr Graeme | Suspended/On hold | NCT02436707 |
Find a Trial
Contact Us